Oxidative stress as a mechanism underlying sulfasalazine-induced toxicity

Bibliography

• Gisbert JP, Gonzalez-Lama Y, Mate J. 5-Aminosalicylates and renal function in inflammatory bowel disease: a systematic review. Inflamm Bowel Dis 2007;13:629-38
   PubMed Web of Science ®Google Scholar
• Plosker GL, Croom KF. Sulfasalazine: a review of its use in the management of rheumatoid arthritis. Drugs 2005;65:1825-49
   PubMed Web of Science ®Google Scholar
• Azad Khan AK, Piris J, Truelove SC. An experiment to determine the active therapeutic moiety of sulphasalazine. Lancet 1977;2:892-5
   PubMed Web of Science ®Google Scholar
• Brzezinski A, Rankin GB, Seidner DL, Lshner BA. Use of old and new oral 5-aminosalicylic acid formulations in inflammatory bowel disease. Cleve Clin J Med 1995;62:317-19
   PubMed Web of Science ®Google Scholar
• Bonner GB, Ruderman WB. Inflammopharmacology. Kluwer Academic, Norwell, Massachusetts; 1993
   Google Scholar
• Ransford RA, Langman MJ. Sulphasalazine and mesalazine: serious adverse reactions re-evaluated on the basis of suspected adverse reaction reports to the Committee on Safety of Medicines. Gut 2002;51:536-9
   PubMed Web of Science ®Google Scholar
• Sands BE. Therapy of inflammatory bowel disease. Gastroenterology 2000;118:S68-82
   PubMed Web of Science ®Google Scholar
• Peppercorn MA, Goldman P. The role of intestinal bacteria in the metabolism of salicylazosulfapyridine. J Pharmacol Exp Ther 1972;181:555-62
   PubMed Web of Science ®Google Scholar
• Brans R, Laizane D, Khan A, Blomeke B. N-Acetyltransferase 2 genotyping: an acccurate and feasible approach for simultaneous detection of the most common NAT2 alleles. Clin Chem 2004;50:1264-6
   PubMed Web of Science ®Google Scholar
• Schroder H, Campbell DE. Absorption, metabolism, and excretion of salicylazosulfapyridine in man. Clin Pharmacol Ther 1972;13:539-51
   PubMed Web of Science ®Google Scholar
• Das KM, Eastwood MA, McManus PA, Sircus W. Adverse reactions during salicylazosulfapyridine therapy and the relation with drug metabolism and acetylator phenotype. N Engl J Med 1973;289:491-5
   PubMed Web of Science ®Google Scholar
• Svartz N. Salazopyrin, a new sulfanilamide preparation. Acta Med Scand 1942;110:577-98
   Google Scholar
• National Toxicology Program (NTP). Toxicology and carcinogenesis studies of salycilazosulphapyridine in F344/N Rats and B6C3F1 mice. National Toxicology Program Technical Report Series. 1997;457:15-21
   Google Scholar
• Sharon P, Ligumsky M, Rachmilewitz D, Zor U. Role of prostagandins in ulcerative colitis, enhanced production during active disease and inhibition by sulfasalazine. Gastroenterology 1978;75:638-40
   PubMed Web of Science ®Google Scholar
• Rogler G, Brand K, Vogl D, Nuclear factor-kB is activated in macrophages and epithelial cells of inflamed intestinal mucosa. Gastroenterology 1998;115:537-69
   Web of Science ®Google Scholar
• Robenbury RJ, Ganga A, Van Lent PL, The anti-inflammatory drug sulfasalazine inhibits tumor necrosis factor alpha expression in macrophages inducing apoptosis. Arthritis Rheum 2000;43:1941-50
   PubMed Web of Science ®Google Scholar
• Pruzauski W, Stefanski E, Vadas P, Ramamurthy NS. Inhibition of extracellular release of pro-inflammatory secretory phospholipase A2 (sPLA2) by sulfasalazine: a novel mechanism of anti-inflammatory activity. Biochem Pharmacol 1997;53:1901-7
   PubMed Web of Science ®Google Scholar
• Barrera P, Boerbooms AM, Van de Putte LBA, Van der Meer JWM. Effect of antirheumatic agents on cytokines. Semin Arthritis Rheum 1996;25:234-53
   PubMed Web of Science ®Google Scholar
• Gan HT, Chen YQ, Ouyang Q. Sulfasalazine inhibits activation of nuclear factor-kappa B in patients with ulcerative colitis. J Gastroenterol Hepatol 2005;20:1016-24
   PubMed Web of Science ®Google Scholar
• Gomez-Munoz A, O'Brien L, Salh B, Steinbrecher UP. 5-Aminosalicylate stimulates phospholipase D activity in macrophages. Biochimica et Biophysica Acta 2001;1533:110-18
   PubMed Web of Science ®Google Scholar
• Wahl C, Liptay S, Adler G, Schmid RM. Sulfasalazine: a potent and specific inhibitor of nuclear factor kappa B. J Clin Invest 1998;101:1163-74
   PubMed Web of Science ®Google Scholar
• Gisbert JP, Gomollon F, Mate J, Pajares JM. Role of 5-aminosalicylic acid (5-ASA) in treatment of inflammatory bowel disease: a systematic review. Dig Dis Sci 2002;47:471-88
   PubMed Web of Science ®Google Scholar
• Levi AJ, Fisher AM, Hughes L, Henry WF. Male infertility due to sulphasalazine. Lancet 1979;314:276-8
   Google Scholar
• Toth A. Male infertility due to sulphasalazine. Lancet 1979;2:904
   PubMed Web of Science ®Google Scholar
• O'Morain C, Smethurst P, Dore CJ, Levi AJ. Reversible male infertility due to sulfasalazine: studies in man and rat. Gut 1984;25:1078-84
   PubMed Web of Science ®Google Scholar
• Didolkar AK, Keizer-Zucker A, Sundaram K, Bardin CW. Effect of sulfasalazine and its analogs on fertility in male rats. Contraception 1988;37:539-48
   PubMed Web of Science ®Google Scholar
• Ueno T, Ishizu K, Baba Y, Antifertility effect of the metabolites of sulfasalazine for male rats. Jpn J Fertil Steril 1990;35:715-20
   Google Scholar
• Sharma RK, Kalla NR. Spermatozoal abnormalities and male infertility in the rat following sulfasalazine treatment. Int J Fertil 1994;39:347-54
   Google Scholar
• Marmor D. The effects of sulphasalazine on male fertility [review]. Reprod Toxicol 1995;9:219-23
   PubMed Web of Science ®Google Scholar
• Hoyt JA, Fisher LF, Swisher DK. Short-term male reproductive toxicity study with sulfasalazine in the rat. Reprod Toxicol 1995;9:315-26
   PubMed Web of Science ®Google Scholar
• Grieve J. Male infertility due to sulphasalazine. Lancet 1979;2:464
   PubMed Web of Science ®Google Scholar
• Toovey S, Hudson E, Hendry WF, Levi AJ. Sulphasalazine and male infertility: reversibility and possible mechanism. Gut 1981;22:445-51
   PubMed Web of Science ®Google Scholar
• Di Paolo MC, Paoluzi OA, Pica R, Sulphasalazine and 5-aminosalicylic acid in long-term treatment of ulcerative colitis: report on tolerante and side-effects. Digest Liver Dis 2001;33:563-9
   Web of Science ®Google Scholar
• Fukushima T, Kato M, Adachi T, Effects of sulfasalazine on sperm acrosome reaction and gene expression in the male reproductive organs of rats. Toxicol Sci 2005;85:675-82
   PubMed Web of Science ®Google Scholar
• Fukushima T, Hamada Y, Komiyama M, Early changes in sperm motility, acrosome reaction, and gene expression of reproductive organs in rats treated with sulfasalazine. Reprod Toxicol 2007;23:153-7
   PubMed Web of Science ®Google Scholar
• Alonso V, Linares V, Belles M, Sulfasalazine induced oxidative stress: a possible mechanism of male infertility. Reprod Toxicol 2009;27:35-40
   PubMed Web of Science ®Google Scholar
• Heetun ZS, Byrnes C, Neary P, O'Morain C. Review article: reproduction in the patient with inflammatory bowel disease [review]. Aliment Pharmacol Ther 2007;26:513-33
   PubMed Web of Science ®Google Scholar
• Zelissen PM, van Hattum J, Poen H, Influence of salazosulphapyridine and 5-aminosalicylic acid on seminal qualities and male sex hormones. Scand J Gastroenterol 1988;23:1100-4
   PubMed Web of Science ®Google Scholar
• Rahimi R, Nikfar S, Rezaie A, Abdollahi M. Pregnancy outcome in women with inflammatory bowel disease following exposure to 5-aminosalicylic acid drugs: a meta-analysis. Reprod Toxicol 2008;25:271-75
   PubMed Web of Science ®Google Scholar
• Norgard B, Czeizel AE, Rockenbauer M, Population based case control study of the safety of sulfasalazine used during pregnancy. Aliment Pharmacol Ther 2001;15:483-86
   PubMed Web of Science ®Google Scholar
• Mogadam M, Dobbins WO, Korelitz BI, Ahmed SW. Pregnancy in inflammatory bowel disease: effect of sulfasalazine and corticosteroids on fetal outcome. Gastroenterology 1981;80:72-6
   PubMed Web of Science ®Google Scholar
• Hernandez-Diaz S, Werler MM, Walker AM, Mitchel AA. Folic acid antagonists during pregnancy and the risk of birth defects. N Engl J Med 2000;343:1608-14
   PubMed Web of Science ®Google Scholar
• Jarnerot G, Anderson S, Esbjorner E, Sandstrom B. Albumin reserve for binding of bilirubin in maternal and cord serum under treatment of sulfasalazine. Scand J Gastroenterol 1981;16:1049-55
   PubMed Web of Science ®Google Scholar
• Esbjorner E, Jarnerot G, Wranne L. Sulphasalazine and sulphapyridine serum levels in children to mothers treated with sulfasalazine during pregnancy and lactation. Acta Paediatr Scand 1987;76:137-42
   PubMed Web of Science ®Google Scholar
• Hamling J, Raedler A, Helmchen U, Schreiber S. 5-Aminosalicylic acid associated renal tubular acidosis with decreased renal function in Crohn's disease. Digestion 1997;58:304-7
   PubMed Web of Science ®Google Scholar
• Dwarakanath AD, Michael J, Allan RN. Sulphasalazine induced renal failure. Gut 1992;33:1006-1007
   PubMed Web of Science ®Google Scholar
• Schreiber S, Hamling J, Zehnter E, Renal tubular dysfunction in patients with inflammatory bowel disease treated with aminosalicylate. Gut 1997;40:761-6
   PubMed Web of Science ®Google Scholar
• Molnar T, Farkas K, Nagy F, Sulfasalazine-induced nephrotic syndrome in a patient with ulcerative colitis. Inflamm Bowel Dis 2009;16:552-3
   Web of Science ®Google Scholar
• Patel H, Barr A, Jeejeebhoy KN. Renal effects of long-term treatment with 5-aminosalicylic acid. Can J Gastroenterol 2009;23:170-6
   PubMed Web of Science ®Google Scholar
• Birketvedt GS, Berg KJ, Fausa O, Florholmen J. Glomerular and tubular renal functions after long-term medication of sulphasalazine, olsalazine, and mesalazine in patients with ulcerative colitis. Inflamm Bowel Dis 2000;6:275-9
   PubMed Web of Science ®Google Scholar
• Augusto JF, Sayegh J, Simon A, A case of sulphasalazine-induced DRESS syndrome with delayed acute interstitial nephritis. Nephrol Dial Transplant 2009;24:2940-2
   PubMed Web of Science ®Google Scholar
• Miura N, Aoyama R, Kitagawa W, Proteinase 3-antineutrophil cytoplasmic antibody-(PR3-ANCA) positive necrotizing glomerulonephritis after restarting sulphasalazine treatment. Clin Nephrol 2009;71:74-9
   PubMed Web of Science ®Google Scholar
• Barbour VM, Williams PF. Nephrotic syndrome associated with sulphasalazine. BMJ 1990;301:818
   PubMed Web of Science ®Google Scholar
• Sharma AK. Sulphasalazine and nephritic syndrome. Am J Gastroenterol 1993;88:1584
   Google Scholar
• Van Staa TP, Travis S, Leufkens HG, Logan RF. 5-Aminosalicylic acids and the risk of renal disease: a large British epidemiologic study. Gastroenterology 2004;126:1733-9
   PubMed Web of Science ®Google Scholar
• Schroeder KM. Role of mesalazine in acute and long-term treatment of ulceratice colitis and its complications [review]. Scand J Gastroenterol Suppl 2002;236:42-7
   PubMedGoogle Scholar
• Corrigan G, Stevens PE. Review article: interstitial nephritis associated with the use of mesalazine in inflammatory bowel disease. Aliment Pharmacol Ther 2000;14:1-6
   PubMed Web of Science ®Google Scholar
• Henning HV, Meinhold J, Eisenhauer T, Chronic interstitial nephritis after treatment with 5-aminosalicylic acid. Dtsch Med Wochenschr 1989;114:1091
   PubMed Web of Science ®Google Scholar
• Chester AC, Diamond LH, Schreiner GE. Hypersensitivity to salicylazosulfapyridine: renal and hepatic toxic reactions. Arch Intern Med 1978;138:1138-9
   PubMed Web of Science ®Google Scholar
• World MJ, Stevens PE, Ashton MA, Rainford DJ. Mesalazineinduced interstitial nephritis. Neprol Dial Transplant 1996;11:614-21
   PubMed Web of Science ®Google Scholar
• Popoola J, Muller AF, Pollock L, Late onset interstitial nephritis. Br Med J 1998;317:795-7
   PubMed Web of Science ®Google Scholar
• Tadic M, Grgurevic I, Scukanec-Spoljar M, Acute interstitial nephritis due to mesalazine. Nephrology (Carlton) 2005;10:103-5
   PubMed Web of Science ®Google Scholar
• Arend LJ, Springate JE. Interstitial nephritis from mesalazine: case report and literature review. Pediatr Nephrol 2004;19:550-3
   PubMed Web of Science ®Google Scholar
• Calder IC, Funder CC, Green CR, Nephrotoxic lesions from 5-aminosalicylic acid. BMJ 1972;1:52-4
   Web of Science ®Google Scholar
• Bilyard KG, Joseph EC, Metcalf R. Mesalazine: an overview of key preclinical studies. Scand J Gastroenterol Suppl 1990;172:52-5
   PubMedGoogle Scholar
• Diener U, Tuczek HV, Fischer C, Renal function was not impaired by treatment with 5-aminosalicylic acid in rats and man. Naunyn Schmiedebergs Arch Pharmacol 1984;326:278-82
   PubMed Web of Science ®Google Scholar
• Green JR, Swan CH, Rowlinson A, Short report: comparison of two doses of balsalazide in maintaining ulcerative colitis in remission over 12 months. Aliment Pharmacol Ther 1992;6:647-52
   PubMed Web of Science ®Google Scholar
• Green JR, Gibson JA, Kerr GD, Maintenance of remission of ulcerative colitis: a comparison between balsalazide 3 g daily and mesalazine 1.2 g daily over 12 months. ABACUS Investigator group. Aliment Pharmacol Ther 1998;12:1207-16
   PubMed Web of Science ®Google Scholar
• Hayllar J, Bjarnason I. Sulphasalazine in ulcerative colitis: in memoriam? Gut 1991;32:462-3
   PubMed Web of Science ®Google Scholar
• Nakajima H, Munakata A, Yoshida Y. Adverse effects of sulfasalazine and treatment of ulcerative colitis with mesalazine. J Gastroenterol 1995;30:115-17
   PubMed Web of Science ®Google Scholar
• Rubin R. Sulfasalazine-induced fulminant hepatic failure and necrotizing pancreatitis. Am J Gastroenterol 1994;89:789-91
   PubMed Web of Science ®Google Scholar
• Marinos G, Riley J, Painter DM, McCaughan GW. Sulfasalazine-induced fulminant hepatic failure. J Clin Gastroenterol 1992;14:132-5
   PubMed Web of Science ®Google Scholar
• McConkey B, Amos RS, Butler EP, Salazopyrin in rheumatoid arthritis. Agents Actions 1994;43:202-5
   PubMedGoogle Scholar
• Senturk T, Aydintug AO, Duzgun N, Tokgoz G. Seizures and hepatotoxicity following sulphasalazine administration. Rheumatol Int 1997;17:75-7
   PubMed Web of Science ®Google Scholar
• Jobanputra P, Amarasena R, Maggs F, Hepatotoxicity associated with Sulfasalazine in inflammatory arthritis: a case series from a local surveillance of serious adverse events. BMC Musculoskelet Disord 2008;9:48
   PubMed Web of Science ®Google Scholar
• Sotolongo RP, Neefe LI, Rudzki C, Ishak KG. Hypersensitivity reaction to sulfasalazine with severe hepatotoxicity. Gastroenterology 1978;75:95-9
   PubMed Web of Science ®Google Scholar
• Gulley RM, Mirza A, Kelly CE. Hepatotoxicity of salicylazosulfapyridine: a case report and review of the literature. Am J Gastroenterol 1979;72:561-4
   PubMed Web of Science ®Google Scholar
• Smith MD, Gibson GE, Rowland R. Combined hepatotoxicity and neurotoxicity following sulphasalazine administration. Aust NZJ Med 1982;12:76-80
   PubMedGoogle Scholar
• Mennicke M, Zawodniak A, Keller M, Fulminant liver failure after vancomycin in a sulfasalazine-induced DRESS syndrome: fatal recurrence after liver transplantation. Am J Transplant 2009;9:2197-202
   PubMed Web of Science ®Google Scholar
• Michel F, Navellou JC, Ferraud D, DRESS syndrome in a patient on sulfasalazine for rheumatoid arthritis [review]. Joint Bone Spine 2005;72:82-5
   PubMed Web of Science ®Google Scholar
• Bejia I, Ben Hammouda S, Riahi K, DRESS syndrome induced by sulphasalazine in rheumatoid arthritis. Joint Bone Spine 2006;73:764-5
   PubMed Web of Science ®Google Scholar
• Teo L, Tan E. Sulphasalazine-induced DRESS. Singapore Med J 2006;47:237-9
   PubMedGoogle Scholar
• Aquino RT, Vergueiro CS, Magliari ME, de Freitas TH. Sulfasalazine-induced DRESS syndrome (Drug Rash with Eosinophilia and Systemic Symptoms). Sao Paulo Med J 2008;126:225-6
   PubMed Web of Science ®Google Scholar
• Kitas G, Farr M, Waterhouse L, Bacon PA. Influence of acetylator status on sulphasalazine efficacy and toxicity in patients with rheumatoid arthritis. Scand J Rheumatol 1992;21:220-5
   PubMed Web of Science ®Google Scholar
• Tanaka E, Taniguchi A, Urano W, Adverse effects of sulfasalazine in patients with rheumatoid arthritis are associated with diplotype configuration at the N-acetyltransferase 2 gene. J Rheumatol 2002;29:2492-9
   PubMed Web of Science ®Google Scholar
• Tanigawara Y, Kita T, Aoyama N, N-acetyltansferase 2 genotype-related sulfapyridine acetylation and its adverse events. Biol Pharm Bull 2002;25:1058-62
   PubMed Web of Science ®Google Scholar
• Chen M, Xia B, Chen B, N-acetyltransferase 2 slow acetylator genotype associated with adverse effects of sulphasalazine in the treatment of inflammatory bowel disease. Can J Gastroenterol 2007;21:155-8
   PubMed Web of Science ®Google Scholar
• Punchard NA, Greenfield SM, Thompson RP. Mechanism of action of 5-arninosalicylic acid. Mediators Inflamm 1992;1:151-65
   PubMedGoogle Scholar
• Rodriguez C, Mayo JC, Sainz RM, Regulation of antioxidant enzymes, a significant role for melatonin, a minireview. J Pineal Res 2004;36:1-9
   PubMed Web of Science ®Google Scholar
• Nicotera TM, Notaro J, Notaro S. Elevated superoxide dismutase in Bloom's syndrome, a genetic condition of oxidative stress. Cancer Res 1989;49:5239-43
   PubMed Web of Science ®Google Scholar
• Gandy J, Millner GC, Bates HK, Effects of selected chemicals on the glutathione status in the male reproductive system of rats. J Toxicol Environ Health 1990;29:45-57
   PubMed Web of Science ®Google Scholar
• Aitken RJ. Sperm function tests and fertility. Int J Androl 2006;29:69-75
   PubMed Web of Science ®Google Scholar
• De Lamirande E, Gagnon C. Impact of reactive oxygen species on spermatozoa: a balancing act between beneficial and detrimental effects. Hum Reprod 1995;10:15-21
   PubMed Web of Science ®Google Scholar
• Pasqualotto FF, Sharma RK, Nelson DR, Relationship between oxidative stress, semen characteristics, and clinical diagnosis in men undergoing infertility investigation. Fertil Steril 2000;73:459-64
   PubMed Web of Science ®Google Scholar
• Fujii J, Iuchi Y, Matsuki S, Ishii T. Cooperative function of antioxidant and redox systems against oxidative stress in male reproductive tissues. Asian J Androl 2003;5:231-42
   PubMed Web of Science ®Google Scholar
• Garrido N, Meseguer M, Simon C, Pro-oxidative and antioxidative imbalance in human semen and its relation with male fertility. Asian J Androl 2004;6:59-65
   PubMed Web of Science ®Google Scholar
• Kobayashi T, Miyazaki T, Natori M, Nozawa S. Protective role of superoxide dismutase in human sperm motility: superoxide dismutase activity and lipid peroxide in human seminal plasma and spermatozoa. Hum Reprod 1991;6:987-91
   PubMed Web of Science ®Google Scholar
• Belles M, Linares V, Albina ML, Melatonin reduces uranium-induced nephrotoxicity in rats. J Pineal Res 2007;43:87-95
   PubMed Web of Science ®Google Scholar
• Linares MV, Sanchez DJ, Belles M, Pro-oxidant effects in the brain of rats concurrently exposed to uranium and stress. Toxicology 2007;236:82-91
   PubMed Web of Science ®Google Scholar
• Sener G, Ozer Sehirli A, Altunbas HZ, Melatonin protects against gentamicin-induced nephrotoxicity in rats. J. Pineal Res 2002;32:231-6
   PubMed Web of Science ®Google Scholar
• Hara M, Yoshida M, Nishijima H, Melatonin, a pineal secretory product with antioxidant properties, protects against cisplatin-induced nephrotoxicity in rats. J Pineal Res 2001;30:129-38
   PubMed Web of Science ®Google Scholar
• Reiter RJ, Tan DX, Manchester LC, Tamura H. Biochemical reactivity of melatonin with reactive oxygen and nitrogen species. A review of the evidence. Cell Biochem Biophys 2001;34:237-56
   PubMed Web of Science ®Google Scholar
• Sener G, Sehirli AO, Ayanoglu-Dulger G. Melatonin protects against mercury(II)-induced oxidative tissue damage in rats. Pharmacol Toxicol 2003;93:290-6
   PubMedGoogle Scholar
• Cetin H, Olgar S, Oktem F, Novel evidence suggesting an anti-oxidant property for erythropoietin on vancomycininduced nephrotoxicity in a rat model. Clin Exp Pharmacol Physiol 2007;34:1181-5
   PubMed Web of Science ®Google Scholar
• De Jesus Soares T, Volpini RA, Francescato HD, Effects of resveratrol on glycerol-induced renal injury. Life Sci 2007;81:647-56
   PubMed Web of Science ®Google Scholar
• Hickey EJ, Raje RR, Reid VE, Diclofenac induced in vivo nephrotoxicity may involve oxidative stress-mediated massive genomic DNA fragmentation and apoptotic cell death. J Clin Endocrinol 2001;31:139-52
   Google Scholar
• Iraz M, Ozerol E, Gulec M, Protective effect of caffeic acid phenethyl ester (CAPE) administration on cisplatin. Cell Biochem Funct 2006;24:357-61
   PubMed Web of Science ®Google Scholar
• Boelsterli UA. Diclofenac-induced liver injury: a paradigm of idiosyncratic drug toxicity. Toxicol Appl Pharmacol 2003;192:307-22
   PubMed Web of Science ®Google Scholar
• Linares V, Alonso V, Albina ML, Lipid peroxidation and antioxidant status in kidney and liver of rats treated with sulfasalazine. Toxicology 2009;256:152-6
   PubMed Web of Science ®Google Scholar
• Maldonado PD, Barrera D, Medina-Campos ON, Aged garlic extract attenuates gentamicin induced renal damage and oxidative stress in rats. Life Sci 2003;73:2543-56
   PubMed Web of Science ®Google Scholar
• Ghosh A, Sil PC. Anti-oxidative effect of a protein from Cajanus indicus L against acetaminophen-induced hepato-nephrotoxicity. J Biochem Mol Biol 2007;40:1039-49
   PubMedGoogle Scholar
• Yilmaz S, Atessahin A, Sahna E, Protective effect of lycopene on adriamycin-induced cardiotoxicity and nephrotoxicity. Toxicology 2006;218:164-71
   PubMed Web of Science ®Google Scholar
• Kovacic P, Cooksy A. Iminium metabolite mechanism for nicotine toxicity and addiction: oxidative stress and electron transfer. Med Hypotheses 2005;64:104-11
   PubMed Web of Science ®Google Scholar
• Luqman S, Rizvi SI. Protection of lipid peroxidation and carbonyl formation in proteins by capsaicin in human erythrocytes subjected to oxidative stress. Phytother Res 2006;20:303-6
   PubMed Web of Science ®Google Scholar
• Nehru LB, Bansal MP6. Effect of selenium supplementation on the glutathione redox system in the kidney of mice after chronic cadmium exposures. J Appl Toxicol 1996;17:81-4
   Web of Science ®Google Scholar
• Arthur JR. The glutathione peroxidases. Cell Mol Life Sci 2000;57:1825-35
   PubMed Web of Science ®Google Scholar
• Beckett GJ, Hayes JD. Glutathione S-transferases: biomedical applications. Adv Clin Chem 1993;30:281-380
   PubMed Web of Science ®Google Scholar
• Hayes JD, Pulford DJ. The glutathione S-tranferase supergene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. Crit Rev Biochem Mol Biol 1995;30:445-600
   PubMed Web of Science ®Google Scholar
• Boesch-Saadatmandi C, Loboda A, Jozkowicz A, Effect of ochratoxin A on redox-regulated transcription factors, antioxidant enzymes and glutathione-S-transferase in cultured kidney tubulus cells. Food Chem Toxicol 2008;46:2665-71
   PubMed Web of Science ®Google Scholar
• Muruganandan S, Gupta S, Kataria M, Mangiferin protects the streptozotocin-induced oxidative damage to cardiac and renal tissues in rats. Toxicology 2002;176:165-76
   PubMed Web of Science ®Google Scholar
• Pedraza-Chaverri J, Barrera D, Maldonado PD, S-allylmercaptocysteine scavenges hydroxyl radical and singlet oxygen in vitro and attenuates gentamicin-induced oxidative and nitrosative stress and renal damage in vivo. BMC Clin Pharmacol 2004;4:5
   PubMedGoogle Scholar
• Chiu PO, Leung HY, Ko KM. Schisandrin B enhances renal mitochondrial antioxidant status, functional and structural integrity, and protects against gentamicin-induced nephrotoxicity in rats. Biol Farm Bull 2008;31:602-5
   PubMed Web of Science ®Google Scholar
• Muthukumaran S, Sudheer A, Menon VP, Nalini N. Protective effect of quercetin on nicotine-induced prooxidant and antioxidant imbalance and DNA damage in Wistar rats. Toxicology 2008;243:207-15
   PubMed Web of Science ®Google Scholar